XBB 1.5, will probably catch this soon

New Omicron Subvariant, Crazy Infectious Dr. Ashish Jha, White House COVID-19 response coordinator https://twitter.com/AshishKJha46/status/1610648627721945088 https://www.medscape.com/viewarticle/986759?src=wnl_recnlnew1_ous_230112_MSCPEDIT_&uac=127834AR&impID=5080457 Spread of XBB.1.5 is stunning 80% of Americans who've already been infected are likely to catch it again https://eu.usatoday.com/story/news/health/2023/01/06/covid-update-xbb-variant-symptoms-reinfection/10995204002/ Dr. Paula Cannon, virologist, University of Southern California It's crazy infectious All the things that have protected you for the past couple of years, I don't think are going to protect you against this new crop of variants Essentially, everyone in the country is at risk for infection now, even if they're super careful, up to date on vaccines, or have caught it before The number of severe infections and deaths remains relatively low, despite the high level of infections, US Variant Proportions https://covid.cdc.gov/covid-data-tracker/#variant-proportions All omicron BQ.1.1 34% XBB.1.5 27.6% BQ.1 21.4% XBB 4.9% BA.5 3.7% BN.1 3% SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 49 11 January 2023 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1128554/variant-technical-briefing-49-11-january-2023.pdf Current high UK incidence England, prevalence 4.5% https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections Primarily of BQ.1 and sub-lineages Hospitalisation (BQ.1) Preliminary analysis, no increase in risk for people with BQ.1 compared to BA.5 Effectiveness of the bivalent booster against hospitalisation with BQ.1 At 2 or more weeks after receiving the booster BQ,1 50.3% BA.5 64.0% XBB First flagged, 11 October 2022 Recombinant lineage 2 BA.2 parent lineages BJ.1 and BM.1.1.1 Advantageous spike mutations from both (about 12 compared to BA.2) More receptor binding domain mutations Plus 23 non spike mutations Rapid replication in primary culture of nasal epithelium XBB.1.5, (Kraken) Currently at low prevalence, 4.5% Has a combination of immune escape and ACE-2 affinity XBB.1.5. has a 38.83% relative growth rate more than BQ.1.1 XBB is phenotypically similar to other Omicron variants, rather than to Delta or earlier variants of concern. CH.1.1 Currently at moderate prevalence Has a 21.56% relative growth rate more than BQ.1.1 Variant prevalence, 26 December 2022 to 1 January 2023 51.3% BQ.1 19.5% CH.1.1 7.2% BA.5 4.9% BA.2.75 4.5% XBB.1.5 3.6% XBB 2.1% were BA.2 0.12% BA.4.6 0.7% classified as other Reports from Variant Technical Group members Neutralisation titres against XBB are the lowest of any contemporary variant tested So, expect post vaccine and post infection breakthrough (Rapid replication in primary culture of nasal epithelium) Current reported covid symptoms in the UK https://health-study.joinzoe.com Blocked nose 57% Sore throat, 57% Runny nose, 53% Headache, 52% Cough no phlegm, 50% Sneezing, 50% Cough with phlegm, 44% Hoarse voice, 40% Muscle pains, 27% Loss of smell, 22% Fatigue, 22% Altered sense smell, 21% Dizzy, light headed, 19% Swollen neck nodes, 19% Earache, 15% Shortness of breath, 16% Chest pain / tightness, 14% Wheezing, 12% Chills / shivers, 12% Learn more about your ad choices. Visit megaphone.fm/adchoices